Report
Description
Report Description
In 2016, Philippines had registered to have the highest incidence of confirmed dengue
among the 10 endemic countries which had participated in clinical efficacy studies for the
vaccine. In April 2016, the first public dengue immunization program was started in the
Philippines. The major launch event which was hosted by the Department of Health
(DoH) of the Philippines, which lists the details about the country’s plan of vaccinating
about 1 million public school children and was shared with the international and national
press during the event. Where in February, Sanofi Pasteur’s dengue vaccine was firstly
made available for the private sector vaccination in the Philippines
Request for TOC: http://www.futuremarketinsights.com/toc/rep-gb-1763
In the history of global burden of diseases, dengue which bears about 70% of it had an
optimism after the first approval of the vaccine. Due to the developments in the recent
years, pharmaceutical companies have started making effort in developing dengue
vaccine and have registered their products for clinical trials. Companies such as
GlaxoSmithKline plc, Merck & Co., Inc. and Takeda Pharmaceutical Company Ltd. are each
at different stages in developing the vaccines for dengue.